Dose-related serious toxicities have limited IL-2 studies in melanoma patients, and low-dose IL-2 therapy has produced disappointing clinical response rates. When high-dose, 100,000 units/kg, intravenous, recombinant IL-2 was examined in 47 patients with metastatic malignant melanoma, up to 20% achieved objective responses; however, three patients developed myocardial infarction and one patient died during therapy. IL-2-based biochemotherapy (IL-2, IFN-α-2b, cisplatin, dacarbazine, and vinblastine) has shown a response rate of 48%. It appears that this combination is statistically superior to either IL-2 or chemotherapy alone. Results of ongoing trials may clarify the true value of IL-2 in combination chemotherapy. ( Table 3 ).
Skin Therapy Letter. 2006;11(5):1-7. © 2006 SkinCareGuide.com
Cite this: Immunological Strategies to Fight Skin Cancer - Medscape - Jun 01, 2006.